Assessment of absorbed dose for Zr-89, Sm-153 and Lu-177 medical radioisotopes: IDAC-Dose2.1 and OLINDA experience

Summary Aim of this study was a characterization of radioiodine therapy (RIT) failures in Graves’ disease without simultaneous Carbimazole. Method: 226 patients with a confirmed diagnosis of Graves’ disease received 686.8 ± 376.4 MBq of iodine-131 orally for thyroid ablation. Target dose was 250 Gy. All patients were followed up for 6 months. Therapy failures were compared with successes regarding possible influencing variables initial thyroid volume, thyroid function, immune activity (TRAb), 1-131 uptake, effective half-life, absorbed energy dose, age and gender. Results: 212 of 226 patients (93.8%) were treated successfully, 14 (6.2%) showed a hyperthyroidism relapse within 6 months which required a second radioiodine therapy. A success rate of 92.5% (62/67) could also be achieved with 67 patients who were hyperthyroid at the time of RIT. Compared to the therapy successes, the 14 failures achieved significantly lower absorbed doses (223.8 ±76.6 Gyvs. 285.2 ±82.1 Gy, ρ <0.005), but with no significant differences regarding age, thyroid volume, function or TRAb (all ρ >0.2). Of the 14 failures, η = 8 reached an absorbed dose <200 Gy and η = 1 a dose <250 Gy, although 5 of the failures reached an absorbed dose of >250 Gy. Stepwise logistic regression revealed only absorbed energy dose as a variable significantly influencing therapy success (p <0.005), but no influence of initial thyroid volume, function, TRAb value, age (all ρ >0.2) or gender (p = 0.13). Two-tailed Fisher’s exact test showed no significant influence of gender on success rates (failures/successes: male 1 /36, female 13/176, ρ = 0.48). Conclusions: Except for the absorbed energy dose, no other significant variable influencing the outcome of radioiodine therapy in Graves’ disease without simultaneous Carbimazole could be found. It should be noted, though, that 5 therapy failures (2.2%) reached an absorbed energy dose of >250 Gy.

Download Full-text

Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies

Nuklearmedizin ◽

10.1055/s-0038-1625927 ◽

2006 ◽

Vol 45 (03) ◽

pp. 134-138 ◽

Cited By ~ 6

Author(s):

T. Kull ◽

N. M. Blumstein ◽

D. Bunjes ◽

B. Neumaier ◽

A. K. Buck ◽

...

Keyword(s):

Monoclonal Antibody ◽

Bone Marrow ◽

Gamma Camera ◽

Absorbed Dose ◽

Correlation Coefficients ◽

Residence Times ◽

Reliable Prediction ◽

Red Bone Marrow ◽

Antibody Preparation ◽

Simplified Method

SummaryAim: For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a 188Re-labelled anti-CD66 monoclonal antibody. Patients, methods: For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 ± 12 years) the residence times were determined for the injected 188Re-labelled anti-CD66 antibodies (1.3 ± 0.4 GBq, 5–7 GBq/mg protein, >95% 188Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i. Results: The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 ± 0.2 h, 1.9 ± 0.8 h, 7.8 ± 2.1 h, 0.6 ± 0.3 h and 8.6 ± 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively. Conclusion: The proposed approach allows reliable prediction of biokinetics of 188Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.

Download Full-text

Superselective Radioembolization of Hepatocellular Carcinoma: 5-Year Results of a Prospective Study

Nuklearmedizin ◽

10.1055/s-0038-1629756 ◽

1994 ◽

Vol 33 (05) ◽

pp. 206-214 ◽

Cited By ~ 1

Author(s):

J. Triller ◽

H. U. Baer ◽

Livia Geiger ◽

H. F. Beer ◽

C. Becker ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Survival Rates ◽

Absorbed Dose ◽

Pulmonary Complications ◽

Pulmonary Shunt ◽

Recurrent Tumour ◽

Activity Distribution ◽

A Prospective Study ◽

Overall Survival Rates

SummaryTwenty patients with unresectable hepatocellular carcinoma (HCC) were followed up to 5 years after transarterial radiotherapy with 90Y-resin particles. Diagnostic radioembolizations of 99mTc-macroaggregates facilitated scintigraphic assessment of activity distribution, dose evaluation and final procedural verification. The overall survival rates were 56, 38 and 14% (after 1, 2 and 3 years, resp.). Patients with unifocal HCC and a single feeding artery (n = 7) even presented 83, 67 and 40% (2 alive after 2.75 and 4 years). With multiple arteries (n = 7), the longest survival was 26 months. Patients with multifocal HCC survived up to 33 months after selective radioembolization. Quality of life was improved in all. Survival was positively correlated with absorbed dose but residual/recurrent tumour occurred even after ≥300 Gy. Post-treatment symptoms were minimal (35 applications), pulmonary shunt rates were correctly predicted and pulmonary complications avoided.

Download Full-text

Predictive parameters of therapy response in PSMA radioligand therapy – correlation of absorbed dose and half-life with pre- and posttherapeutic SUV in 68 Ga-PSMA-11 PET

10.1055/s-0040-1708391 ◽

2020 ◽

Author(s):

F Völter ◽

A Gosewisch ◽

L Kaiser ◽

FJ Gildehaus ◽

A Todica ◽

...

Keyword(s):

Half Life ◽

Absorbed Dose ◽

Therapy Response ◽

Radioligand Therapy ◽

Predictive Parameters

Download Full-text

National primary standard of absorbed dose and absorbed dose rate of beta radiation in tissue-equivalent material GET 9–2018

Izmeritel`naya Tekhnika ◽

10.32446/0368-1025it.2019-7-3-9 ◽

2019 ◽

pp. 3-9

Author(s):

S. A. Fedina ◽

A.V. Oborin ◽

A.Y. Villevalde ◽

E.N. Rumyantseva ◽

S.G. Trofimchuk

Keyword(s):

Dose Rate ◽

Primary Standard ◽

Absorbed Dose ◽

Beta Radiation ◽

Equivalent Material ◽

Absorbed Dose Rate ◽

National Primary Standard ◽

Tissue Equivalent

Download Full-text

Estimation of Absorbed Dose in Solar Cell Arrays Returned from MIR Space Station

10.2514/6.iac-03-i.5.02 ◽

2003 ◽

Author(s):

Denis Makhotin

Keyword(s):

Solar Cell ◽

Space Station ◽

Absorbed Dose ◽

Cell Arrays

Download Full-text

Skin exposure: requirements to methods determining active ingredient of pesticides in washings

Russian Journal of Occupational Health and Industrial Ecology ◽

10.31089/1026-9428-2018-9-43-48 ◽

2019 ◽

pp. 43-48

Author(s):

V. N. Rakitskii ◽

N. E. Fedorova ◽

I. V. Bereznyak ◽

N. G. Zavolokina ◽

L. P. Muhina

Keyword(s):

Lower Limit ◽

Limit Of Detection ◽

Solid Phase ◽

Absorbed Dose ◽

Ambient Air ◽

Safety Coefficient ◽

Limit Value ◽

Calculated Risk ◽

Nature Studies ◽

Active Substances

The article presents results of studies exemplified by diquat on analysis concerning inﬂuence of lower limit value of quantitative assessment in washing sample for safety coefficient in exposure and in absorbed dose, if acting substance is absent in workplace ambient air samples and in dermal washings of workers. To control diquat in dermal washings, there is a method based on ion-pair liquid chromatography with ultraviolet detection (working wavelength 310 nm). To concentrate sample, cartridges for solid-phase extraction, containing ion exchange sorbent (Oasis MCX 6cc/500 mg), are used. Lower limit of assessment in washing sample — 0,15 micrograms. Experimentally set washing completeness is within range of 80–92%, standard deviation of repetition is 7,0% at most. The method created was tested in nature studies determining dermal exposure in workers subjected to 5 various preparations based on diquat dibromide when used for surface spraying from tractor and from aircraft. For lower limit of detection in washing sample (0,15 micrograms/washing), calculated risk value of exposure varied within 0,26–0,36; risk of absorbed dose was low — 0,23 (the allowable one ≤1). Findings are that present measuring methods which provide lower limit of detection 1 and 5 micrograms in washing sample could result in unallowable risk establishment even with absence of the substance in all samples of workplace air and dermal washings. The calculation formula suggested enables to give theoretic basis for requirements to lower limit of detecting active substances in dermal washing samples for evaluating risk of pesticides use in agriculture.

Download Full-text